Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2 by Yang, Xi et al.
RESEARCH Open Access
Characterization of Epstein-Barr virus (EBV)-
infected cells in EBV-associated hemophagocytic
lymphohistiocytosis in two patients with X-linked


















Background: X-linked lymphoproliferative syndrome (XLP) is a rare inherited immunodeficiency by an extreme
vulnerability to Epstein-Barr virus (EBV) infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH).
XLP are now divided into type 1 (XLP-1) and type 2 (XLP-2), which are caused by mutations of SH2D1A/SLAM-
associated protein (SAP) and X-linked inhibitor of apoptosis protein (XIAP) genes, respectively. The diagnosis of XLP in
individuals with EBV-associated HLH (EBV-HLH) is generally difficult because they show basically similar symptoms
to sporadic EBV-HLH. Although EBV-infected cells in sporadic EBV-HLH are known to be mainly in CD8
+ T cells, the
cell-type of EBV-infected cells in EBV-HLH seen in XLP patients remains undetermined.
Methods: EBV-infected cells in two patients (XLP-1 and XLP-2) presenting EBV-HLH were evaluated by in EBER-1 in
situ hybridization or quantitative PCR methods.
Results: Both XLP patients showed that the dominant population of EBV-infected cells was CD19
+ B cells, whereas
EBV-infected CD8
+ T cells were very few.
Conclusions: In XLP-related EBV-HLH, EBV-infected cells appear to be predominantly B cells. B cell directed therapy
such as rituximab may be a valuable option in the treatment of EBV-HLH in XLP patients.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is clinically
characterized by prolonged fever, hepatosplenomegaly,
hypertriglyceridemia, systemic hypercytokinemia and
cytopenia [1]. HLH consists of primary (familial) and
secondary (infection, lymphoma or autoimmune disease-
associated) types. Approximately half of all infection-
associated HLH cases involves the Epstein-Barr virus
(EBV) [2]. Most cases of EBV-HLH are sporadic, but a
few cases may present the first presentation of X-linked
lymphoproliferative syndrome (XLP) [3]. XLP is a rare,
inherited immunodeficiency that is characterized by an
extreme vulnerability to EBVi n f e c t i o na n ds h o w sv a r i -
able clinical phenotypes, including severe or fatal EBV-
HLH (60%), malignant B-cell lymphoma (30%), and pro-
gressive dysgammaglobulinemia (30%) [3]. The first
genes that is responsible for XLP was identified as the
SH2D1A/SLAM-associated protein (SAP) gene in 1998
[4-6], and mutations in the X-linked inhibitor of apopto-
sis protein (XIAP) gene can also lead to the clinical phe-
notype of XLP in 2006 [7]. XLP is now considered to
comprise two distinct diseases, namely XLP-1 (SAP defi-
ciency) and XLP-2 (XIAP deficiency).
In addition to B cells, EBV can infect other cell types,
including epithelial cells, T cells and natural killer (NK)
cells [8]. Studies have shown that activated T cells,
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+ T cells, are the primary cellular target
of EBV infection in sporadic EBV-HLH [9,10], which
reflects the pathogenic role of EBV-infected CD8
+ T
cells in sporadic EBV-HLH. Patients with sporadic EBV-
HLH are usually treated with immunochemotherapy,
including dexamethasone, cyclosporine A and etoposide,
and this therapy can be curable [11]. In contrast, XLP-
related EBV-HLH is usually refractory to immunochem-
otherapy [3]. It is possible that the poor response of
XLP-related EBV-HLH to immunochemotherapy can be
attributed to the type of EBV-infected cells in this dis-
ease, which may differ from the cell type that infected in
sporadic EBV-HLH. We investigated the affected cell
type in EBV infection of two XLP (XLP-1 and XLP-2)
patients with EBV-HLH. Our results demonstrate that
the predominant EBV target cells in XLP-related EBV-
HLH are CD19
+ B cells, which appears to be distinct
from sporadic EBV-HLH cases.
Patients, materials and methods
Patients
Three patients presented with clinical features of HLH,
including persistent fever, hepatosplenomegaly, cytope-
nia, abnormal liver function, hyperferritinemia and ele-
vated levels of soluble interleukin-2-receptor (Table 1).
The clinical features of the patients fulfilled the diagnos-
tic criteria for HLH [1], although hemophagocytosis in
the bone marrow was not observed in patients 1 and 2.
Patient 3 was previously reported as patient HLH3 [10].
The number of EBV-DNA copies in the peripheral
b l o o dw a si n c r e a s e df r o mt h en o r m a ll e v e lo f≤ 1×1 0
2
copies/ml to 1.4 × 10
5, 5.7 × 10
3 and 1.4 ×10
6 copies/ml
in patients 1, 2 and 3, respectively. Blood samples from
the patients were obtained using standard ethical proce-
dures with the approval of the Ethics Committee of the
University of Toyama, and an analysis of the SH2D1A
and XIAP genes was performed. Patient 1 showed a
one-nucleotide insertion (239_240insA) in the SH2D1A
gene that resulted in a frameshift and a premature stop
codon (80KfsX22). Patient 2 carried a two-nucleotides
deletion (1021_1022delAA) in the XIAP gene that
resulted in a frameshift and a premature stop codon
(N341YfsX7). Patient 3 had no mutations in the
SH2D1A or XIAP gene.
Cell preparation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from the the patients using Ficoll-Hypaque gradi-
ent centrifugation. Lymphocytes were prepared from the
PBMCs by depleting the monocytes using anti-CD14
monoclonal antibody (mAb)-coated magnetic beads
(Becton Dickinson, San Diego, CA) [10]. The CD19
+ B
cells, CD56
+ NK cells, CD4
+ T cells and CD8
+ T cells
were purified by positive selection from the lymphocytes
using the respective mAb-coated magnetic beads. The
purity of each isolated cell population was assessed by
flow cytometriy analysis, and each sorted population
was found to be higher than 85% pure.
In situ hybridization of EBVRNA
The presence of EBV was estimated by measuring the
EBV-encoded small RNA 1 (EBER-1) mRNA using the
in situ hybridization (ISH) method as described pre-
viously [10]. The sorted cells were cytocentrifuged onto
silanized slides (Dako, Kyoto, Japan), and the presence
of EBER-1 mRNA was determined by ISH using the
alkaline phosphatase-conjugated EBER-1 antisense probe
(5’-AGCAGAGTCTGGGAAGACAACCACAGA-
CACCGTCCTCACC-3’) or a sense probe.
Quantitative PCR for EBV DNA
Quantitative PCR was performed using AmpliTaq Gold
and a real-time PCR 7300 system (Applied Biosystems,
Foster City, CA) as described previously [12]. The PCR
primers for detecting EBV DNA were selected from
within the BALF5 gene, which encodes the viral DNA
polymerase. The primers for amplifying the BALF5 gene
sequences were as follows: forward, CGGAAGCCC
TCTGGACTTC, and reverse, CCCTGTT TATCC-
GATGGAATG. The TaqMan probe was FAM-TATA-
CACGCACGAGAAATGCGCC-BFQ. The PCR
Table 1 Clinical and laboratory finding of the patients in
this study
Patient 1 Patient 2 Patient 3
Family history available No Yes No
Age at the time of the study 4 years 21 months 16 months
Age at onset 3 years 17 months 16 month
Fever Yes Yes Yes
Hepatomegaly 4 cm 5 cm 2.5 cm
Splenomegaly 2 cm 3 cm 1 cm
White blood cells (×10
9/L) 11.6 6.36 3.03
Neutrophils (×10
9/L) 1.61 3.915 0.56
Hemoglobin (g/dL) 8.1 9.6 7.5
Platelets (×10
9/L) 95 56 30
LDH (IU/L) 449 1,693 1,698
AST (IU/L) 88 122 453
ALT (IU/L) 31 25 255
Ferritin (μg/L) 1,276 26,282 11,129
sIL-2R (U/mL) 3,162 2,880 14,334
IgG (mg/dL) 1,821 806 423
IgA (mg/dL) 302 124 32
IgM (mg/dL) 1,843 40 18
Whole blood EBV-DNA (copies/mL) 140,000 5,700 1,400,000
LDH, lactate dehydrogenase; AST, aspartate amino transferase; ALT, alanine
amino transferase, sIL-2R, soluble interleukin-2 receptor; NA: not available.
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minutes, annealing at 58°C for 15 seconds, and exten-
sion at 72°C for 15 seconds, and the products were sub-
jected to 45 cycles of PCR amplification. The EBV DNA
copy number was considered to be significant when
more than 500 copies/μg of DNA were observed.
Flow cytometry analysis for the T cell receptor Vb
repertoire
Flow cytometry analysis of the T cell receptor (TCR) Vb
repertoire was performed as described previously [10].
In briefl, the PBMCs were incubated with the appropri-
ate phycoerythrin-conjugated mAbs with specificity for
TCR Vb 1-23 (Immunotech, Marseille, France), fluores-
cein isothiocyanate-conjugated anti-CD8 (Becton Dick-
inson) and R-PE-Cy5-conjugated anti-CD4 (Dako)
mAbs. The stained cells were analyzed using a flow cyt-
ometer. TCR Vb expression is represented as the per-
centage of CD4
+ or CD8
+ cells for each receptor family.
Results
To determine the localization of EBV infection in the
lymphocyte subpopulations of patient 1, CD4
+ T cells,
CD8
+ T cells, CD19
+ B cells and CD56
+ NK cells were
sorted using the immunomagnetic bead method and the
presence of EBV was evaluated in each lymphocyte sub-
population by EBER-1 ISH (Figure 1A). EBER-1-positive
cells were observed in 34.0% of the CD19
+ Bc e l l s ,
whereas the remaining lymphocyte subpopulations con-
tained fewer than 0.1% EBER-1-positive cells. Therefore,
the EBV-infected cells in patient 1 were almost exclu-
sively CD19
+ B cells. In patient 3, EBER-1-positive cells
constituted 75.5% of CD8
+ T cells, however, they were
not detected among CD4
+ T cells and observed in a few
of CD19
+ B cells and CD56
+ NK cells (2.8% and1 7.4%,
respectively) (Figure 1B).
The viral loads in the CD4
+ Tc e l l s ,C D 8
+ T cells,
CD19
+ B cells and CD56
+ NK cells in patient 2 were
determined by quantitative PCR. The number of EBV
DNA genome copies in the CD19
+ B cells was 1.8 × 10
4
copies/μg, and the copy number in the CD8
+ T cells
was 1.0 × 10
3 copies/μg .T h eE B VD N Ag e n o m ec o u l d
not be detected in either the CD4
+ T cells or the CD56
+
NK cells that were isolated from patient 2.
Flow cytometry analysis of the TCR Vb repertoire
revealed a polyclonal pattern in patients 1 and 2 (Figure
2), which was in contrast to the skewed pattern that is
most commonly seen in the CD8
+ T cells of patients
with sporadic EBV-HLH [10]. No clonal dominance in
CD8
+ T cells was demonstrated by mAb in patient 3,
but TCR Vb13.3 was predominantly found in the CD8
+
T cells by complentarity-determining region 3 spectra-
typing [10].
Discussion
XLP is a severe and rare immunodeficiency disease that
is characterized by an extreme vulnerability to EBV
infection and frequently results in HLH [3]. XLP was
first described as X-linked progressive combined immu-
nodeficiency in 1975 by Purtilo et al. [13]. To better
understand and reflect the pathophysiology of this dis-
ease, the term “X-linked lymphoproliferative disease or
syndrome” has now been used. The first gene to be
linked to XLP in 1998 was SH2D1A which is located on
Xq25 and encodes the SAP [4-6]. Importantly, in 2006,
a mutation in the gene that encodes the XIAP was iden-
tified as a second XLP-linked gene [7]. Thus, XLP can
be divided into XLP-1 (SAP deficiency) and XLP-2
(XIAP deficiency). Most XLP patients present with
EBV-HLH. Pachlopnik Schmid et al. [14] reported that
the incidence of HLH in XLP-1 and XLP-2 is 55 and
76%, respectively. Currently, hematopoietic stem cell
transplantation (HSCT) is the only curative therapy for
XLP. Therefore, an early definitive diagnosis and
immediate treatment are extremely important for both
life-saving intervention and an improved prognosis for
XLP patients.
EBV infects the majority of the adult population
worldwide and persists in B cells throughout the lifetime
of normal individuals, usually without causing disease.
EBV is the most common trigger for both the XLP-1
and XLP-2 phenotypes. Prior to being exposed to EBV,
most patients with XLP can tolerate infections by other
agents, although in vitro studies have demonstrated
defects of T cell-mediated and humoral immunity. Dur-
ing an acute EBV infection, XLP patients develop nor-
mal or high levels of anti-viral capsid antigen IgM
antibodies but usually lack heterophile antibodies. Initi-
ally, these patients fail to develop EBV-specific cytotoxic
T cells, and this results in a massive and overwhelming
polyclonal B cell proliferation involving lymphoid and
other tissues [8]. SAP binds 2B4, which is a surface
molecule involved in activation of NK cell-mediated
cytotoxity. Therefore, SAP-deficient patient shows that
NK cell function is impaired, allowing B cell prolifera-
tion [15]. SAP has proapoptotic function, and contri-
butes to the maintenance of T cell homeostasis and to
the elimination of potentially dangerous DNA-damaged
cells. Thus, the loss of this function could be responsible
for the uncontrol T cell proliferation in acute EBV
infection [16].
B cells are the usual cellular targets of EBV in a pri-
mary EBV infection such as infectious mononucleosis
and in the sero-positive normal host [8]. After the inter-
action of the viral surface glycoproteins with the CD21
receptor, EBV entry into B cells is mediated by HLA
class II and other co-receptors. However, in cases of
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NK cells [9,10,17]. The mechanism of T cell infection
by EBV in HLH is still unclear, but one hypothesis is
that, in specific situations, CD8
+ T cells express CD21,
which can mediate EBV infection. Although T cells do
not express the glycoprotein, they contain mRNA for
CD21 [18]. In sporadic EBV-HLH cases, EBV infection
into B cells is delayed but occurs during every case of
c u r e dE B V - H L H[ 1 7 ] .T ot h eb e s to fo u rk n o w l e d g e ,
this is the first report of EBV infection status in two dif-
ferent types of XLP patients with EBV-HLH. The pre-
sent study shows that the primary EBV-infected cells in
XLP-related EBV-HLH are CD19
+ B cells and not T
cells or NK cells, which are a primary target of EBV
infection in sporadic EBV-HLH.
For decades, clinicians and investigators have been
puzzled by the differential diagnosis between XLP and
sporadic EBV-HLH when they encountered a young
boy presenting with EBV- HLH. We believe the differ-
ent EBV target cells can provide additional information
to help discriminate between XLP and sporadic EBV-
HLH. An evaluation of specific cell type that is
infected by EBV should be considered when target
therapy is applied. Most patients with sporadic EBV-
HLH can achieve remission by immunochemotherapy;
however, patients with XLP are usually refractory to
this therapy. Recently, B cell-directed therapy using an
anti-CD20 mAb (rituximab) was performed in patients
with XLP-1 [19]. Two XLP patients who presented
with acute EBV infection were successfully treated
with rituximab and were free from EBV-HLH and lym-
phoma for a prolonged period. In addition, rituximab
combined with methylprednisolone and intravenous
immunoglobulin were administered to an XLP-1
patient with EBV-HLH, and the patient achieved a
remission [20]. Patient 1 was also associated with EBV-
associated encephalitis and lymphoproliferative disor-
der. The patient’s lymphoproliferative disorder was
treated with rituximab, but he died of the disease.
Patient 2 was successfully treated with dexamethasone
Figure 1 Cytospin preparations showing EBER-1 in situ hybridization of the lymphocyte subpopulations. Lymphocyte subpopulations
from patients 1 and 3 were separated by magnetic bead sorting after immunostaining with anti-CD4, CD8, CD19 or CD56 mAbs. EBV infection
in each subpopulation was determined using EBER-1 ISH. A, In patient 1, EBER-1-positive cells (shown by their dark nuclear staining) were
detected in34.0% of the B cells but were not detected in CD4
+ T cells, CD8
+ T cells or CD56
+ NK cells (< 0.1% each). B, In patient 3, EBER-1-
positive cells were observed in 75.5% of CD8
+ T cells, 2.8% of CD19
+ B cells, and 17.4% of CD56
+ NK cells, but not observed in CD4
+ T cells [10].
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get therapy can be a viable therapeutic option for an
initial stage of EBV-HLH in both XLP-1and XLP-2
patients.
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Figure 2 The results of the flow cytometric analysis of TCR Vb. The expression profiles of the TCR Vb subfamilies of patients 1, 2 and 3. The
PBMCs were stained with mAbs for individual TCR Vb, together with an anti-CD8 mAb. The percentage of the expression of each TCR Vb within
CD8
+ T cells was analyzed by flow cytometry.
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